Cellegesic Draws Split Vote On Need For New Study On Anal Fissure Pain
Cellegy's Cellegesic for anal fissures may or may not need a new study for approval following a split decision by FDA's Cardiovascular and Renal Drugs Advisory Committee at its April 25 meeting
You may also be interested in...
FDA is on pace to hold fewer advisory committee meetings in 2007 than in 2006
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011